Immunohistochemical Expression of P53 in Renal Cell Carcinoma Subtypes
Ekspresi Imunohistokimia P53 pada Subtipe Karsinoma Sel Ginjal
Keywords:
P53, Renal Cell Carcinoma, Immunohistochemistry, Clear Cell RCC, Clinicopathological CorrelationAbstract
General Background: Renal cell carcinoma (RCC) constitutes approximately 2.2% of global cancer incidences and is predominantly of the clear cell subtype. Specific Background: The tumor suppressor gene p53, frequently mutated in over half of human cancers, plays a critical prognostic role in various malignancies. However, Knowledge Gap: its prognostic significance in RCC remains controversial due to inconsistent findings across histopathological parameters and RCC subtypes. Aims: This study aimed to evaluate the immunohistochemical expression of p53 in RCC subtypes and its association with clinicopathological parameters including age, sex, laterality, grade, lymphovascular invasion, and tumor stage. Results: Among 65 RCC cases, p53 expression was observed in only 6.2%, confined exclusively to the clear cell subtype, and predominantly in older males with higher tumor grades (III/IV) and early stages (T1–T2). No statistically significant association was found with any examined parameters. Novelty: The study underscores the rarity of p53 expression in RCC and its subtype-specific occurrence, contrasting with previously reported higher expression rates in other populations. Implications: These findings suggest limited prognostic utility of p53 in RCC within this demographic, and highlight the necessity for standardized methodologies and further multicenter studies to clarify p53’s role.
Highlight :
-
P53 expression ditemukan hanya pada 6.2% kasus RCC dan seluruhnya dari subtipe clear cell RCC.
-
Tidak ditemukan hubungan statistik signifikan antara ekspresi P53 dan parameter klinikopatologi seperti usia, jenis kelamin, grade, dan stadium.
-
Ekspresi P53 cenderung lebih banyak muncul pada pasien laki-laki berusia ≥55 tahun, grade tinggi (3–4), dan lokasi ginjal kanan.
Keywords : P53, Renal Cell Carcinoma, Immunohistochemistry, Clear Cell RCC, Clinicopathological Correlation
References
[1] M. Li et al., "Liquid Biopsy at the Frontier in Renal Cell Carcinoma: Recent Analysis of Techniques and Clinical Application," Molecular Cancer, vol. 22, no. 1, p. 37, 2023, doi: 10.1186/s12943-023-01745-7.
[2] A. M. Kase, D. J. George, and S. Ramalingam, "Clear Cell Renal Cell Carcinoma: From Biology to Treatment," Cancers, vol. 15, no. 3, p. 665, 2023, doi: 10.3390/cancers15030665.
[3] X. D. Song et al., "Research Progress on Advanced Renal Cell Carcinoma," Journal of International Medical Research, vol. 48, no. 6, p. 0300060520924265, 2020, doi: 10.1177/0300060520924265.
[4] Z. Wang et al., "Prognostic and Clinicopathological Value of P53 Expression in Renal Cell Carcinoma: A Meta-Analysis," Oncotarget, vol. 8, no. 60, pp. 102361–102371, 2017, doi: 10.18632/oncotarget.21971.
[5] S. Gupta, C. W. Devadass, S. Varshney, and S. P. Babu, "Histopathological Evaluation and Analysis of Immunohistochemical Markers P53 and CD44S in Renal Cell Carcinoma: A Cross-Sectional Study," Journal of Clinical and Diagnostic Research, vol. 17, no. 7, 2023, doi: 10.7860/JCDR/2023/63352.18192.
[6] A. Amendolare et al., "The Underestimated Role of the P53 Pathway in Renal Cancer," Cancers, vol. 14, no. 23, p. 5733, 2022, doi: 10.3390/cancers14235733.
[7] M. Radovanović et al., "P53 and Survivin Expression in Renal Cell Carcinoma," Urology Annals, vol. 15, no. 2, pp. 186–190, 2023, doi: 10.4103/ua.ua_91_22.
[8] J. Godlewski et al., "Expression and Prognostic Significance of EP300, TP53 and BAX in Clear Cell Renal Cell Carcinoma," Anticancer Research, vol. 37, no. 6, pp. 2927–2937, 2017, doi: 10.21873/anticanres.11646.
[9] F. Li et al., "Kidney Cancer Biomarkers and Targets for Therapeutics: Survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, P53, KRAS and AKT in Renal Cell Carcinoma," Journal of Experimental and Clinical Cancer Research, vol. 40, no. 1, p. 254, 2021, doi: 10.1186/s13046-021-02026-1.
[10] F. Baytekin et al., "Significance of P-Glycoprotein, P53, and Survivin Expression in Renal Cell Carcinoma," Urologic Oncology: Seminars and Original Investigations, vol. 29, no. 5, pp. 502–507, 2011, doi: 10.1016/j.urolonc.2009.09.001.
[11] M. A. Habib, M. J. Ibrahim, and S. D. Farhan, "P53 in Renal Cell Carcinoma: A Biomarker for Disease Progression," Journal of the Faculty of Medicine Baghdad, vol. 53, no. 1, pp. 54–56, 2011, doi: 10.32007/jfacmedbagdad.531911.
[12] S. Jumaa, A. Al-Janabi, and Z. A. Al-Ali, "Pathological Study of Renal Cell Carcinoma by Expression of Vascular Endothelial Growth Factor (VEGF) and P53," Kerbala Journal of Medicine, vol. 4, no. 10, pp. 1128–1132, 2011.
[13] F. Noroozinia et al., "Expression of CD44 and P53 in Renal Cell Carcinoma: Association with Tumor Subtypes," Saudi Journal of Kidney Diseases and Transplantation, vol. 25, no. 1, pp. 79–84, 2014, doi: 10.4103/1319-2442.124495.
[14] A. A. Elbendary et al., "Relationship Between P21 Expression and Mutation of the P53 Tumor Suppressor Gene in Normal and Malignant Ovarian Epithelial Cells," Clinical Cancer Research, vol. 2, no. 9, pp. 1571–1575, 1996.
[15] S. P. Vasavada, A. C. Novick, and B. R. Williams, "P53, Bcl-2, and Bax Expression in Renal Cell Carcinoma," Urology, vol. 51, no. 6, pp. 1057–1061, 1998, doi: 10.1016/S0090-4295(98)00132-0.
[16] R. Kabaria, Z. Klaassen, and M. K. Terris, "Renal Cell Carcinoma: Links and Risks," International Journal of Nephrology and Renovascular Disease, vol. 9, pp. 45–52, 2016, doi: 10.2147/IJNRD.S75916.
[17] I. Hodorova et al., "Investigation of Tumour Suppressor Protein P53 in Renal Cell Carcinoma Patients," Biomedical Papers, vol. 158, no. 1, pp. 44–49, 2014, doi: 10.5507/bp.2012.035.
[18] D. L. Uhlman et al., "Association of Immunohistochemical Staining for P53 With Metastatic Progression and Poor Survival in Patients With Renal Cell Carcinoma," JNCI: Journal of the National Cancer Institute, vol. 86, no. 19, pp. 1470–1475, 1994, doi: 10.1093/jnci/86.19.1470.
[19] K. Zheng et al., "Retrospective Analysis of a Large Patient Sample to Determine P53 and Ki67 Expressions in Renal Cell Carcinoma," Journal of BUON, vol. 19, no. 2, pp. 512–516, 2014.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nour D. Taha, Wahda M.T. Al-Nuaimy
This work is licensed under a Creative Commons Attribution 4.0 International License.
